Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study – Telix Pharmaceuticals | Telix Pharmaceuticals

Our mission is to help patients with cancer live longer with better quality lives

Source: Telix Pharmaceuticals

Categories: Latest Headlines, Oncologists2

Tweets with this article

The Uro-Oncologist

Amazing news, after many years and efforts CAIX becomes a reality! Can’t wait to see innovative trials design with it incorporation! Here’s the link btw https://t.co/I8VfpBd29c https://t.co/x6qdqAnuxB

A Matched Analysis of Active Surveillance Versus Nephrectomy for T1a Small Renal Masses

In a cohort of patients with a small renal mass (SRM) matched for age and health status, 5-yr outcomes for those managed with active surveillance…

The Uro-Oncologist October 28, 2023

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial

CheckMate -901 is the first and only Phase 3 trial with an immunotherapy-based combination to demonstrate a survival benefit compared to standard-of-care cisplatin-based combinations in…

The Uro-Oncologist July 11, 2023

The Uromigos

Striving to provide balanced, scientific content related to care of patients with GU malignancies. …

The Uro-Oncologist February 13, 2023